Sanders Morris Harris LLC Acquires Shares of 87,054 uniQure N.V. $QURE

Sanders Morris Harris LLC purchased a new stake in uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 87,054 shares of the biotechnology company’s stock, valued at approximately $5,081,000. uniQure comprises 0.7% of Sanders Morris Harris LLC’s portfolio, making the stock its 22nd largest holding.

Other large investors have also recently added to or reduced their stakes in the company. Swiss National Bank acquired a new position in shares of uniQure during the 2nd quarter worth approximately $1,080,000. Aberdeen Group plc increased its stake in uniQure by 24.2% during the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after acquiring an additional 535,163 shares during the period. Jennison Associates LLC bought a new stake in shares of uniQure during the 2nd quarter valued at $1,952,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of uniQure during the 2nd quarter worth $872,000. Finally, JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of QURE opened at $21.89 on Wednesday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.36 billion, a PE ratio of -4.99 and a beta of 0.59. uniQure N.V. has a 12-month low of $7.76 and a 12-month high of $71.50. The business has a 50-day simple moving average of $39.59 and a two-hundred day simple moving average of $26.52.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. Analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insider Buying and Selling at uniQure

In related news, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the transaction, the director owned 40,145 shares in the company, valued at $1,094,352.70. This trade represents a 43.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 314,560 shares of company stock worth $12,362,568 over the last ninety days. Insiders own 4.79% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on QURE shares. Chardan Capital reiterated a “buy” rating and set a $53.00 price objective on shares of uniQure in a research note on Thursday, December 4th. William Blair reissued a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Monday, December 8th. Stifel Nicolaus reduced their target price on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Finally, Guggenheim boosted their price target on uniQure from $28.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $60.82.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.